Incidence of Early Atrial Fibrillation After Transcatheter versus Surgical Aortic Valve Replacement: A Meta-Analysis of Randomized Controlled Trials.
Atrial fibrillation
Meta-analysis
SAVR
TAVR
Journal
Journal of atrial fibrillation
ISSN: 1941-6911
Titre abrégé: J Atr Fibrillation
Pays: United States
ID NLM: 101514767
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
11
06
2020
revised:
15
06
2020
accepted:
25
07
2020
entrez:
24
12
2021
pubmed:
25
12
2021
medline:
25
12
2021
Statut:
epublish
Résumé
Post-operative atrial fibrillation (POAF) is common after aortic valve replacement (AVR) and is associated with worse outcomes. We performed a meta-analysis of randomized controlled trials comparing Surgical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) for incidence of POAF at 30 days. We searched databases from 1/1/1990 to 1/1/2020 for randomized studies comparing TAVR and SAVR. POAF was defined as either worsening or new-onset atrial fibrillation. Random effects model was used to estimate the risk of POAF with TAVR vs SAVR in all trials, and in subgroups (low, intermediate, high risk, and in self-expandable vs balloon expandable valves). Sensitivity analysis was performed including only studies reporting new-onset atrial fibrillation. Seven RCTs were identified that enrolled 7,934 patients (3,999 to TAVR and 3,935 to SAVR). The overall incidence of POAF was 9.7% after TAVR and 33.3% after SAVR. TAVR was associated with a lower risk of POAF compared with SAVR (OR 0.21 [0.18-0.24]; P < 0.0001). Compared with SAVR, TAVR was associated with a significantly lower risk of POAF in the high-risk cohort (OR 0.37 [0.27-0.49]; P < 0.0001), in the intermediate-risk cohort (OR 0.23 [0.19-0.28]; P < 0.0001), low-risk cohort (OR 0.13 [0.10-0.16]; P < 0.0001). Sensitivity analysis of 4 trials including only new-onset POAF showed similar summary estimates (OR 0.21, 95% CI [0.18-0.25]; P< 0.0001). TAVR is associated with a significantly lower risk of post-operative atrial fibrillation compared with SAVR in all strata. Further studies are needed to identify the contribution of post-operative atrial fibrillation to the differences in clinical outcomes after TAVR and SAVR.
Sections du résumé
BACKGROUND
BACKGROUND
Post-operative atrial fibrillation (POAF) is common after aortic valve replacement (AVR) and is associated with worse outcomes. We performed a meta-analysis of randomized controlled trials comparing Surgical Aortic Valve Replacement (SAVR) and Transcatheter Aortic Valve Replacement (TAVR) for incidence of POAF at 30 days.
METHODS
METHODS
We searched databases from 1/1/1990 to 1/1/2020 for randomized studies comparing TAVR and SAVR. POAF was defined as either worsening or new-onset atrial fibrillation. Random effects model was used to estimate the risk of POAF with TAVR vs SAVR in all trials, and in subgroups (low, intermediate, high risk, and in self-expandable vs balloon expandable valves). Sensitivity analysis was performed including only studies reporting new-onset atrial fibrillation.
RESULTS
RESULTS
Seven RCTs were identified that enrolled 7,934 patients (3,999 to TAVR and 3,935 to SAVR). The overall incidence of POAF was 9.7% after TAVR and 33.3% after SAVR. TAVR was associated with a lower risk of POAF compared with SAVR (OR 0.21 [0.18-0.24]; P < 0.0001). Compared with SAVR, TAVR was associated with a significantly lower risk of POAF in the high-risk cohort (OR 0.37 [0.27-0.49]; P < 0.0001), in the intermediate-risk cohort (OR 0.23 [0.19-0.28]; P < 0.0001), low-risk cohort (OR 0.13 [0.10-0.16]; P < 0.0001). Sensitivity analysis of 4 trials including only new-onset POAF showed similar summary estimates (OR 0.21, 95% CI [0.18-0.25]; P< 0.0001).
CONCLUSIONS
CONCLUSIONS
TAVR is associated with a significantly lower risk of post-operative atrial fibrillation compared with SAVR in all strata. Further studies are needed to identify the contribution of post-operative atrial fibrillation to the differences in clinical outcomes after TAVR and SAVR.
Identifiants
pubmed: 34950322
doi: 10.4022/jafib.2411
pmc: PMC8691290
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2411Références
Am J Cardiol. 2012 Jun 1;109(11):1637-43
pubmed: 22424581
BMJ. 1997 Dec 6;315(7121):1533-7
pubmed: 9432252
J Am Coll Cardiol. 2018 Nov 13;72(20):2415-2426
pubmed: 30442284
N Engl J Med. 2014 May 8;370(19):1790-8
pubmed: 24678937
Circ Cardiovasc Interv. 2016 Jan;9(1):e002766
pubmed: 26733582
Ann Intern Med. 2001 Dec 18;135(12):1061-73
pubmed: 11747385
Am J Cardiol. 2019 Apr 1;123(7):1127-1133
pubmed: 30683423
JACC Cardiovasc Interv. 2018 Nov 12;11(21):2207-2216
pubmed: 30409278
JAMA Intern Med. 2019 Aug 1;179(8):1122-1130
pubmed: 31157821
N Engl J Med. 2019 May 2;380(18):1706-1715
pubmed: 30883053
JAMA. 1996 Jul 24-31;276(4):300-6
pubmed: 8656542
J Am Coll Cardiol. 2012 Jan 10;59(2):178-88
pubmed: 22177537
Circulation. 2017 Jun 20;135(25):e1159-e1195
pubmed: 28298458
J Am Coll Cardiol. 2012 Sep 11;60(11):971-7
pubmed: 22921973
N Engl J Med. 2019 May 2;380(18):1695-1705
pubmed: 30883058
Heart Lung Circ. 2020 Oct;29(10):1542-1553
pubmed: 32327310
J Am Coll Cardiol. 2015 May 26;65(20):2184-94
pubmed: 25787196
Circulation. 1996 Aug 1;94(3):390-7
pubmed: 8759081
Ann Thorac Surg. 1993 Sep;56(3):539-49
pubmed: 8379728
N Engl J Med. 2017 Apr 6;376(14):1321-1331
pubmed: 28304219
Ann Thorac Surg. 2012 Jan;93(1):124-31
pubmed: 22115334
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Heart Lung. 2020 Mar - Apr;49(2):186-192
pubmed: 31690493
Curr Pharm Des. 2016;22(13):1896-903
pubmed: 26642773
Internist (Berl). 2019 Nov;60(11):1221-1224
pubmed: 31486860
N Engl J Med. 2011 Jun 9;364(23):2187-98
pubmed: 21639811